Information Provided By:
Fly News Breaks for July 25, 2017
CTSO
Jul 25, 2017 | 08:38 EDT
Aegis analyst Evan Wang assumed coverage of CytoSorbents with a Buy rating and $9 price target, as he believes the company's CytoSorb technology for removing excess cytokines from the blood can drive operating profitability by the end of 2018. Wang noted he is "conservatively assuming" initiation of U.S. sales in cardiac applications in 2020.
News For CTSO From the Last 2 Days
There are no results for your query CTSO